Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA says [CNBC]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: CNBC
quarter of this year as demand jumps, according to an update on the Food and Drug Administration's drug shortage database on Wednesday. All doses of Zepbound and Mounjaro besides the 2.5-milligram versions of both treatments are in shortage. A previous update said some doses of both drugs would have limited availability through April. The new update suggests that the insatiable demand for a buzzy class of weight loss and diabetes drugs is still trouncing supply , even as Eli Lilly and its main rival Novo Nordisk work to increase production of those treatments. Many patients are struggling to find the injectable treatments , which have soared in demand for helping them shed significant pounds over time. Those treatments are sometimes known as incretin drugs, which mimic gut hormones to suppress appetite and regulate blood sugar. Eli Lilly did not immediately respond to a request for comment on the FDA's update on Wednesday. Eli Lilly in February said it has achieved its goal
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Lilly Raises 2024 Guidance as Zepbound Keeps Flying Off Shelves [BNN Bloomberg (Canada)]BNN Bloomberg
- Chasing Novo and Lilly: The obesity drugs that could challenge Wegovy and Zepbound [Yahoo! Finance]Yahoo! Finance
- How expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk [Yahoo! Finance]Yahoo! Finance
- Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings? [Yahoo! Finance]Yahoo! Finance
- UPDATE 1-One dose of Novo Nordisk's Wegovy back in supply, FDA website shows [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/3/23 - Beat
NVO
Sec Filings
- 4/26/24 - Form 6-K
- 4/25/24 - Form 6-K
- 4/25/24 - Form 6-K
- NVO's page on the SEC website